Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Quality of Life Assessment
100%
Renal Transplantation
100%
Immunoprophylaxis
100%
Antithymocyte Globulin
100%
Basiliximab
100%
Quality-adjusted Survival
37%
Induction Therapy
37%
First Year
25%
Quality of Life
25%
Treatment Costs
25%
Renal Transplant Recipients
25%
Clinical Outcomes
12%
Hospitalization
12%
Treatment Group
12%
High Risk
12%
Clinical High Risk
12%
High-risk Subjects
12%
Immunosuppressive Therapy
12%
Therapy Regimen
12%
Medical Resources
12%
Immunosuppressive Regimens
12%
Cyclosporine
12%
Chimeric Monoclonal Antibody
12%
Open-label Clinical Trial
12%
EuroQol-Visual Analogue Scale
12%
Nursing and Health Professions
Quality of Life Assessment
100%
Kidney Transplantation
100%
Thymocyte Antibody
100%
Basiliximab
100%
Immunoprophylaxis
100%
Kidney Graft
25%
Post Hoc Analysis
25%
Quality of Life
25%
Clinical Outcome
12%
Immunosuppressive Treatment
12%
Immunosuppressive Agent
12%
Monoclonal Antibody
12%
Ciclosporin
12%
Visual Analog Scale
12%
Treatment Group
12%
Clinical Trial
12%
Immunology and Microbiology
Kidney Transplantation
100%
Anti-Thymocyte Globulin
100%
Basiliximab
100%
Monoclonal Antibody
12%
Immunosuppressive Drug
12%
Immunosuppressive Therapy
12%
Ciclosporin
12%
Pharmacology, Toxicology and Pharmaceutical Science
Basiliximab
100%
Thymocyte Antibody
100%
Immunosuppressive Agent
25%
Clinical Trial
12%
Monoclonal Antibody
12%
Ciclosporin
12%
Treatment Group
12%